Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Wright

Psychiatry Lake Charles, LA Medical Doctor

NPI 1174753453 CMS profile 710458

2829 4Th Ave Ste 150, Lake Charles, LA 70601

Open in the dashboard

General payments

$2,747

134 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Wright of Lake Charles, LA is reported in the CMS Open Payments database as having received $2,747 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $674 29
2024 General $213 5
2023 General $534 23
2022 General $354 20
2021 General $433 27
2020 General $84 5
2019 General $454 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Wright
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Michael Wright were reported at $674. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Michael Wright Psychiatry median Middle half National median
2019 $454 $184 $59–$605 $163
2020 $84 $119 $36–$372 $114
2021 $433 $143 $43–$576 $132
2022 $354 $153 $50–$590 $149
2023 $534 $170 $56–$651 $160
2024 $213 $179 $57–$673 $164
2025 $674 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,047 54 payments
  2. Sunovion Pharmaceuticals Inc. $227 16 payments
  3. Neurocrine Biosciences, Inc. $221 5 payments
  4. Otsuka America Pharmaceutical, Inc. $214 8 payments
  5. ITI, Inc. $169 7 payments
  6. Axsome Therapeutics, Inc. $145 3 payments
  7. Alkermes, Inc. $139 8 payments
  8. Janssen Pharmaceuticals, Inc $101 6 payments
  9. Lundbeck LLC $80 4 payments
  10. Allergan Inc. $72 5 payments
  11. Other $331 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,747 134 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $995 51 payments
  2. LATUDA $227 16 payments
  3. INGREZZA $188 3 payments
  4. Auvelity $145 3 payments
  5. CAPLYTA $145 6 payments
  6. VRAYLAR Neuroscience $124 8 payments
  7. ABILIFY MAINTENA $123 2 payments
  8. ARISTADA Cns $123 7 payments
  9. ARISTADA Cns $123 7 payments
  10. ARISTADA Cns $102 6 payments
  11. Other $1,092 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

707

Median for Psychiatry: 574

Drug cost

$34,341

Median for Psychiatry: $27,624

Branded share of claims

21.2%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 33 $19,847
Fetzima Levomilnacipran Hcl Brand 12 $5,761
Sertraline Hcl Generic 23 $1,093
Quetiapine Fumarate Generic 72 $918
Bupropion Hcl Sr Bupropion Hcl Brand 36 $563
Mirtazapine Generic 37 $541
Trazodone Hcl Generic 27 $503
Hydroxyzine Pamoate Generic 24 $494
Gabapentin Generic 33 $455
Bupropion Xl Bupropion Hcl Brand 13 $437

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$6,257

Medicare's payments for the services billed

Medicare patients

25

Average age 58

Services billed

76

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Arthritis 44%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $140
$140 — —
VRAYLAR
  • AbbVie, Inc. $55
$55 — —
REXULTI
  • Lundbeck LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record